BOLD
Price
$1.42
Change
+$0.11 (+8.40%)
Updated
Apr 17 closing price
Capitalization
31.67M
31 days until earnings call
CLRPF
Price
$1.09
Change
-$0.06 (-5.22%)
Updated
Apr 16 closing price
Capitalization
386.89M
Ad is loading...

BOLD vs CLRPF

Header iconBOLD vs CLRPF Comparison
Open Charts BOLD vs CLRPFBanner chart's image
Boundless Bio
Price$1.42
Change+$0.11 (+8.40%)
Volume$64.6K
Capitalization31.67M
Clarity Pharmaceuticals
Price$1.09
Change-$0.06 (-5.22%)
Volume$1.04K
Capitalization386.89M
BOLD vs CLRPF Comparison Chart
Loading...
BOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BOLD vs. CLRPF commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLD is a Hold and CLRPF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (BOLD: $1.42 vs. CLRPF: $1.09)
Brand notoriety: BOLD and CLRPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLD: 81% vs. CLRPF: 9%
Market capitalization -- BOLD: $31.67M vs. CLRPF: $386.89M
BOLD [@Biotechnology] is valued at $31.67M. CLRPF’s [@Biotechnology] market capitalization is $386.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLD’s FA Score shows that 1 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).

  • BOLD’s FA Score: 1 green, 4 red.
  • CLRPF’s FA Score: 0 green, 5 red.
According to our system of comparison, BOLD is a better buy in the long-term than CLRPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLD’s TA Score shows that 5 TA indicator(s) are bullish.

  • BOLD’s TA Score: 5 bullish, 3 bearish.

Price Growth

BOLD (@Biotechnology) experienced а +19.33% price change this week, while CLRPF (@Biotechnology) price change was +1.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

BOLD is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLRPF($387M) has a higher market cap than BOLD($31.7M). BOLD YTD gains are higher at: -51.034 vs. CLRPF (-59.667). CLRPF (-66.98M) and BOLD (-67.75M) have comparable annual earnings (EBITDA) .
BOLDCLRPFBOLD / CLRPF
Capitalization31.7M387M8%
EBITDA-67.75M-66.98M101%
Gain YTD-51.034-59.66786%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash167MN/A-
Total Debt121KN/A-
TECHNICAL ANALYSIS
Technical Analysis
BOLD
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
89%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
BOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WWIAX11.37N/A
N/A
Westwood Income Opportunity A
NWKCX77.25N/A
N/A
Nationwide Geneva Small Cap Gr R6
PRJAX38.17N/A
N/A
PGIM Jennison Global Opportunities A
ALCBX11.37N/A
N/A
ALPS/Smith Balanced Opportunity C
EPIVX11.96N/A
N/A
EuroPac International Value A

BOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, BOLD has been loosely correlated with PRME. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BOLD jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLD
1D Price
Change %
BOLD100%
+8.40%
PRME - BOLD
35%
Loosely correlated
N/A
DSGN - BOLD
33%
Loosely correlated
+3.55%
DNA - BOLD
33%
Loosely correlated
-2.97%
ETXPF - BOLD
32%
Poorly correlated
N/A
KYMR - BOLD
32%
Poorly correlated
+3.80%
More

CLRPF and

Correlation & Price change

A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRPF
1D Price
Change %
CLRPF100%
N/A
SBHMY - CLRPF
24%
Poorly correlated
N/A
BOLD - CLRPF
23%
Poorly correlated
+8.40%
HEPA - CLRPF
22%
Poorly correlated
-6.09%
AKBA - CLRPF
21%
Poorly correlated
+8.42%
DOSEF - CLRPF
12%
Poorly correlated
N/A
More